---
title: "VK2735 in Chronic weight management: VK2735-102 part 2 oral and subcutaneous maintenance"
description: "Formulary evidence on VK2735 in Chronic weight management: VK2735-102 part 2 oral and subcutaneous maintenance. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 2 further headings. 27 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence/vk2735-102-part-2-oral-and-subcutaneous-maintenance"
published: "2026-11-15T21:45:47-05:00"
modified: "2026-11-15T21:45:47-05:00"
---

# VK2735 in Chronic weight management: VK2735-102 part 2 oral and subcutaneous maintenance

<a id="heading-3.1.8"></a>

## 3.1.8 VK2735-102 Part 2 Oral and Subcutaneous Maintenance

<a id="heading-3.1.8.1"></a>

### 3.1.8.1 Objective

<a id="topic-3.1.8.1-1"></a>

#### Oral and additional subcutaneous maintenance regimens after subcutaneous induction

> “Part 2 of the study is designed to explore the potential of various VK2735 oral tablet dosing regimens as well as additional subcutaneous dosing regimens to maintain the initial weight loss achieved from weekly subcutaneous dosing.”
> “The study objectives are to evaluate the safety, tolerability, and pharmacokinetic profile of VK2735 under these various dosing regimens. Exploratory endpoints will assess changes in body weight from baseline and from Week 21 to the end of the study at Week 33.”

Source: [Viking Therapeutics oral maintenance study initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-06-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Maintenance-Dosing-Clinical-Trial-in-Patients-with-Obesity)

<a id="topic-3.1.8.1-2"></a>

#### Question the company expects Part 2 to answer

> “With the second part of the maintenance study, we are very interested in seeing how a person's weight change responds when you go from this weekly subcutaneous injection to a daily oral dose administration. We have not seen that really with any dual agonist just yet.”

Source: [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)

<a id="topic-3.1.8.1-3"></a>

#### Brief summary in the ClinicalTrials.gov record

> “The goal of this Phase 1, randomized, double-blind, placebo-controlled study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VK2735 in adults who are obese (BMI ≥ 30 kg/m2) without comorbidities.”

Source: [ClinicalTrials.gov NCT07838740](https://clinicaltrials.gov/study/NCT07838740)

<a id="heading-3.1.8.2"></a>

### 3.1.8.2 Location and Study Date

<a id="topic-3.1.8.2-1"></a>

#### Initiation in October 2026

> “SAN DIEGO, Oct. 6, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of an exploratory oral maintenance dosing study of VK2735”
> “The trial announced today is the second in a two-part maintenance study initiated in 2025.”

Source: [Viking Therapeutics oral maintenance study initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-06-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Maintenance-Dosing-Clinical-Trial-in-Patients-with-Obesity)

<a id="topic-3.1.8.2-2"></a>

#### Results expected in 2027

> “The company expects the results from Part 2 of this study to be available in 2027.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

> “SC to oral maintenance study underway; data expected 2027”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

<a id="topic-3.1.8.2-3"></a>

#### Study dates and United States sites in the ClinicalTrials.gov record (both study parts)

| Field | Registry value |
| --- | --- |
| Recruitment status | “Recruiting” |
| Primary completion (estimated) | “2027-05” |
| Study completion (estimated) | “2027-07” |
| Site 1 city | “Lake Forest” |
| Site 2 city | “Miami” |

Source: [ClinicalTrials.gov NCT07838740](https://clinicaltrials.gov/study/NCT07838740)

<a id="heading-3.1.8.3"></a>

### 3.1.8.3 Study Design

<a id="topic-3.1.8.3-1"></a>

#### Design announced at initiation, including weekly oral doses

> “Study to Explore Oral Maintenance Dosing Regimens Following Initial Weight Loss with Subcutaneous VK2735”
> “The maintenance dosing study is a randomized, double-blind, placebo-controlled trial in approximately 195 adults with obesity (BMI ≥30 kg/m2) who are otherwise healthy. As in Part 1 of the study, all participants will receive initial weekly subcutaneous doses of VK2735 or placebo for 21 weeks. Following Week 21, participants will transition to a range of VK2735 maintenance dosing options including daily oral doses, weekly oral doses, monthly subcutaneous doses, every-other-week subcutaneous doses, or placebo.”

Source: [Viking Therapeutics oral maintenance study initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-06-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Maintenance-Dosing-Clinical-Trial-in-Patients-with-Obesity)

<a id="topic-3.1.8.3-2"></a>

#### Correction removing the weekly oral regimen

> “Correction Note: The company's press release issued on October 6, 2026, entitled, Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity, incorrectly stated that the trial would be evaluating, "weekly oral doses." The trial will be evaluating maintenance dosing options including daily oral doses, monthly subcutaneous doses, every-other-week subcutaneous doses, or placebo.”

Source: [Viking Therapeutics SUNRISE initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity)

<a id="topic-3.1.8.3-3"></a>

#### Corrected design in the third quarter results

> “Part 2 of the study is a randomized, double-blind, placebo-controlled trial in approximately 195 adults with obesity (BMI ≥30 kg/m2) who are otherwise healthy. As in Part 1, all participants will receive initial weekly subcutaneous doses of VK2735 for 21 weeks. Following Week 21, participants will transition to a range of VK2735 maintenance dosing options including daily oral doses, monthly subcutaneous doses, every-other-week subcutaneous doses, or placebo.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

<a id="topic-3.1.8.3-4"></a>

#### Reason given for not including a weekly oral regimen

> “We thought that because the single dose variability is quite high with the oral route of administration, that it might be better to look at multiple different dose levels on the daily basis. We also added more cohorts on the subQ side as well.”

Source: [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)

<a id="topic-3.1.8.3-5"></a>

#### Same protocol and template as Part 1

> “The oral maintenance will follow the same template as this study. 21 weeks of sub-Q dosing, and then we will have a 12-week period of maintenance dosing. Same overall trial design. It is under the same protocol”

Source: [Viking Therapeutics maintenance study topline call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/758817-study-result/)

<a id="topic-3.1.8.3-6"></a>

#### Part B in the ClinicalTrials.gov record

> “Participants in Part B will be randomized equally across 6 treatment arms to receive one of four VK2735 dose regimens or matching placebo regimen. Each study part is comprised of treatment periods 1 and 2, lasting 21 weeks and 12 weeks, respectively. Study participants may receive a different dosing frequency and/or route of administration between the two periods.”
> “Part A will be completed prior to the enrollment of Part B.”

Source: [ClinicalTrials.gov NCT07838740](https://clinicaltrials.gov/study/NCT07838740)

<a id="heading-3.1.8.4"></a>

### 3.1.8.4 Eligibility Criteria

<a id="topic-3.1.8.4-1"></a>

#### Adults with obesity who are otherwise healthy

> “Part 2 of the study is a randomized, double-blind, placebo-controlled trial in approximately 195 adults with obesity (BMI ≥30 kg/m2) who are otherwise healthy.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

<a id="topic-3.1.8.4-2"></a>

#### Inclusion criteria in the ClinicalTrials.gov record (both study parts)

> “Must be medically healthy, with no significant medical history, have no clinically significant abnormalities on physical examination at Screening and/or before administration of the initial dose of IP in the opinion of the study Investigator.”
> “BMI ≥ 30 kg/m2.”

Source: [ClinicalTrials.gov NCT07838740](https://clinicaltrials.gov/study/NCT07838740)

<a id="topic-3.1.8.4-3"></a>

#### Exclusion criteria in the ClinicalTrials.gov record (both study parts)

> “Current or past diagnosis of diabetes mellitus (including type 1 and type 2, except gestational diabetes).”
> “Have a personal or family history of medullary thyroid carcinoma (MTC) or have multiple endocrine neoplasia syndrome type 2 (MEN-2).”
> “Any surgical or medical condition (active or chronic) that may interfere with IP distribution, metabolism, excretion or drug absorption.”

Source: [ClinicalTrials.gov NCT07838740](https://clinicaltrials.gov/study/NCT07838740)

<a id="heading-3.1.8.5"></a>

### 3.1.8.5 Treatment

<a id="topic-3.1.8.5-1"></a>

#### Subcutaneous formulation: weekly induction for 21 weeks

> “As in Part 1 of the study, all participants will receive initial weekly subcutaneous doses of VK2735 or placebo for 21 weeks.”

Source: [Viking Therapeutics oral maintenance study initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-06-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Maintenance-Dosing-Clinical-Trial-in-Patients-with-Obesity)

<a id="topic-3.1.8.5-2"></a>

#### Oral formulation: daily maintenance doses up to 55 mg in five arms

> “No, we'll look at a range of doses there, ranging from around 17 to 55. We have five arms there. We haven't disclosed those doses yet. But that's the range we'll look at in the oral part of the study, and that's week 21 to 33.”
> “With the oral in the maintenance, we're looking at a daily dose, so we probably wouldn't exceed the registration doses that are going up to 55 mg in the SUNRISE study.”

Source: [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)

<a id="topic-3.1.8.5-3"></a>

#### Oral formulation: doses named at the top-line call

> “doses that we talked about there are 17.5 mg, 27.5 mg, and 55 mg.”

Source: [Viking Therapeutics maintenance study topline call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/758817-study-result/)

<a id="topic-3.1.8.5-4"></a>

#### Subcutaneous formulation: six every-other-week and monthly maintenance arms

> “Then we have six subQ arms, three every other week and three monthly as well in that study.”

Source: [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)

<a id="topic-3.1.8.5-5"></a>

#### Part B treatment arms in the ClinicalTrials.gov record

| Arm label | Registry description |
| --- | --- |
| “VK2735 Dose Level 13” | “VK2735 subcutaneously weekly followed by VK2735 orally weekly” |
| “VK2735 Dose Level 14” | “VK2735 subcutaneously weekly followed by VK2735 orally once daily” |
| “VK2735 Dose Level 15” | “VK2735 subcutaneously weekly followed by VK2735 orally once daily” |
| “VK2735 Dose Level 16” | “VK2735 subcutaneously weekly followed by VK2735 orally once daily” |
| “VK2735 Dose Level 17” | “VK2735 subcutaneously weekly followed by Placebo orally once weekly” |
| “VK2735 Dose Level 18” | “VK2735 subcutaneously weekly followed by Placebo orally once daily” |

Source: [ClinicalTrials.gov NCT07838740](https://clinicaltrials.gov/study/NCT07838740)

<a id="topic-3.1.8.5-6"></a>

#### Interventions in the ClinicalTrials.gov record

| Intervention | Registry description |
| --- | --- |
| VK2735 | “SC or oral once daily, once weekly, every other week, or monthly” |
| Placebo | “SC or oral once daily or once weekly” |

Source: [ClinicalTrials.gov NCT07838740](https://clinicaltrials.gov/study/NCT07838740)

<a id="heading-3.1.8.6"></a>

### 3.1.8.6 Study Outcomes

<a id="heading-3.1.8.6.1"></a>

#### 3.1.8.6.1 Rationale for Using Treatment-emergent Adverse Events as the Primary Endpoint

<a id="topic-3.1.8.6.1-1"></a>

##### Registered primary and secondary outcome measures

| Outcome | Measure | Description | Time frame |
| --- | --- | --- | --- |
| Primary | “Evaluate the Safety and Tolerability VK2735” | “Incidence of treatment emergent adverse events (TEAEs) and treatment emergent serious adverse events (TESAEs)” | “33 weeks” |
| Secondary | “Evaluate the Pharmacokinetic profile of VK23735” | “Pharmacokinetic profile of oral VK2735 by measuring peak plasma concentration (Cmax) after daily or weekly administration” | “38 weeks” |

Source: [ClinicalTrials.gov NCT07838740](https://clinicaltrials.gov/study/NCT07838740)

<a id="topic-3.1.8.6.1-2"></a>

##### Body weight as an exploratory endpoint

> “Study objectives are to evaluate the safety, tolerability, and pharmacokinetic profile of VK2735 under these various dosing regimens. Exploratory endpoints will assess changes in body weight from baseline and from Week 21 to the end of the study at Week 33.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

<a id="heading-3.1.8.7"></a>

### 3.1.8.7 Statistical Analysis Description

<a id="heading-3.1.8.7.1"></a>

#### 3.1.8.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.8.7.1-1"></a>

##### Planned enrollment of approximately 195 participants

> “Part 2 of the study is a randomized, double-blind, placebo-controlled trial in approximately 195 adults with obesity (BMI ≥30 kg/m2) who are otherwise healthy.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

<a id="topic-3.1.8.7.1-2"></a>

##### Estimated enrollment across both parts in the ClinicalTrials.gov record

> “Approximately 270 participants will be enrolled across two study parts: Part A and Part B.”

Source: [ClinicalTrials.gov NCT07838740](https://clinicaltrials.gov/study/NCT07838740)

<a id="heading-3.1.8.7.2"></a>

#### 3.1.8.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.8.8"></a>

### 3.1.8.8 Results

<a id="heading-3.1.8.8.1"></a>

#### 3.1.8.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.8.8.2"></a>

#### 3.1.8.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.8.8.3"></a>

#### 3.1.8.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.8.8.4"></a>

#### 3.1.8.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.8.8.5"></a>

#### 3.1.8.8.5 Safety Results

No evidence found.

<a id="heading-3.1.8.9"></a>

### 3.1.8.9 Study Limitations

<a id="topic-3.1.8.9-1"></a>

#### Summary: study limitations

Part 2 of the VK2735-102 study began in October 2026, and no results have been reported; the company expects results in 2027. It is a phase 1 trial in approximately 195 otherwise healthy adults with a body mass index of at least 30 kg/m2, with a 12-week maintenance period after 21 weeks of weekly subcutaneous induction, a primary endpoint of treatment-emergent adverse events, and body weight change as an exploratory endpoint. The documents disagree on the regimens. The initiation release of 6 October 2026 listed “weekly oral doses”, and a correction note issued on 14 October 2026 removed them; the ClinicalTrials.gov record still lists a group receiving VK2735 “orally weekly” and a group receiving placebo “orally once weekly”. The registry describes 6 Part B arms receiving “one of four VK2735 dose regimens or matching placebo regimen”, while the chief executive officer described five oral arms and six subcutaneous arms. The oral doses have not been disclosed; the September 2026 call named 17.5, 27.5, and 55 mg, and the October 2026 call gave a range of about 17 to 55 mg. The registry estimate of 270 participants for both parts is smaller than the sum of the 180 participants randomized in Part 1 and the approximately 195 planned for Part 2.

Source: [Viking Therapeutics oral maintenance study initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-06-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Maintenance-Dosing-Clinical-Trial-in-Patients-with-Obesity); [Viking Therapeutics SUNRISE initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity); [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update); [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/); [Viking Therapeutics maintenance study topline call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/758817-study-result/); [ClinicalTrials.gov NCT07838740](https://clinicaltrials.gov/study/NCT07838740)

<a id="topic-3.1.8.9-2"></a>

#### Uncertain response after the step down from weekly subcutaneous to daily oral dosing

> “No, that one's a little bit of a hard one to predict because the exposures, when you go from 17.5 mgs weekly down to a lower daily oral dose, are just going to be such a jump in exposures. It's offset by the fact that you're dosing daily. But hard to know how those will play out longer term.”

Source: [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)

## Related pages
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management.md)
- [VK2735 in Chronic weight management: Terms and abbreviations](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations.md)
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary.md)
- [VK2735 in Chronic weight management: Product information and disease description](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description.md)
- [VK2735 in Chronic weight management: Clinical evidence](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence.md)
- [VK2735 in Chronic weight management: Economic information and modeling report](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics.md)
- [VK2735 in Chronic weight management: References](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references.md)
